Clarithromycin dissolution enhancement by preparation of aqueous nanosuspensions using sonoprecipitation technique

Iranian Journal of Pharmaceutical Research

Volumn 13, Issue 3, 2014, Pages 809-818

  Esfandi, Es'hagh ^a   Ramezani, Vahid ^a,b   Vatanara, Alireza ^a   Najafabadi, Abdolhossein Rouholamini ^a   Hadipour Moghaddam, Seyyed Pouya ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antimicrobial activity; Clarithromycin; Nanosuspension; Solubility; Stabilizer

Indexed keywords

CARBOXYMETHYLCELLULOSE; CLARITHROMYCIN; HYDROXYPROPYLMETHYLCELLULOSE; POLOXAMER; POLYSORBATE 80; POLYVINYL ALCOHOL; STABILIZING AGENT;

AGAR DIFFUSION; ANTIMICROBIAL ACTIVITY; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KLEBSIELLA PNEUMONIAE; PARTICLE SIZE; PH; PSEUDOMONAS AERUGINOSA; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS; SUSPENSION; THERMAL ANALYSIS; ULTRASOUND; ZETA POTENTIAL;

EID: 84905110851     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bolourchian N, Mahboobian MM and Dadashzadeh S. The effect of PEG molecular weights on dissolution behavior of Simvastatin in solid dispersions. Iran. J. Pharm. Res. (2011) 12: 11-20.
2. Saeedi M, Akbari J, Morteza-Semnani K, Enayati-Fard R, Sar-Reshteh-dar S and Soleymani A. Enhancement of dissolution rate of indomethacin: using liquisolid compacts. Iran. J. Pharm. Res. (2011) 10: 25.
3. Samei M, Vatanara A, Fatemi S and Rouholamini Najafabadi A. Process variables in the formation of nanoparticles of megestrol acetate through rapid expansion of supercritical CO2. J. Supercrit. Fluids (2012) 70: 1-7.
4. Rabinow BE. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. (2004) 3: 785-796.
5. Moschwitzer J, Achleitner G, Pomper H and Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. (2004) 58: 615-619.
6. Kesisoglou F, Panmai S and Wu Y. Nanosizing--oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. (2007) 59: 631-644.
7. Jacobs C and Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. (2002) 19: 189-194.
8. Muller RH, Gohla S and Keck CM. State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery. Eur. J. Pharm. Biopharm. (2011) 78:1-9.
9. Keck CM and Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. (2006) 62: 3-16.
10. Merisko-Liversidge E, Liversidge GG and Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. (2003) 18: 113-120.
11. Cho E, Cho W, Cha KH, Park J, Kim MS, Kim JS, Park HJ and Hwang SJ. Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives. Int. J. Pharm. (2010) 396: 91-98.
12. Shekunov BY, Chattopadhyay P, Seitzinger J and Huff R. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm. Res. (2006) 23: 196-204.
13. Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH and Hwang SJ. Preparation, characterization and in-vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. (2008) 69: 454-465.
14. Kondo M, Niwa T, Okamoto H and Danjo K. Particle characterization of poorly water-soluble drugs using a spray freeze drying technique. Chem. Pharm. Bull. (2009) 57: 657-662.
15. Rogers TL, Nelsen AC, Hu J, Brown JN, Sarkari M, Young TJ, Johnston KP and Williams RO. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: Spray-freezing into liquid. Eur. J. Pharm. Biopharm. (2002) 54: 271-280.
16. Sarkari M, Brown J, Chen X, Swinnea S, Williams Iii RO and Johnston KP. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int. J. Pharm. (2002) 243: 17-31.
17. Li C, Le Y and Chen JF. Formation of bicalutamide nanodispersion for dissolution rate enhancement. Int. J. Pharm. (2011) 404: 257-263.
18. Kesisoglou F, Panmai S and Wu Y. Nanosizing-Oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. (2007) 59: 631-644.
19. Nakagawa Y, Itai S, Yoshida T and Nagai T. Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparison with erythromycin. Chem. Pharm. Bull. (1992) 40: 725-728.
20. Peters DH and Clissold SP. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs (1992) 44: 117-164.
21. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin. Pharm. (1999) 37: 385-398.
22. Lobenberg R and Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. (2000) 50: 3-12.
23. Li J, Nie S, Yang X, Wang C, Cui S and Pan W. Optimization of tocol emulsions for the intravenous delivery of clarithromycin. Int. J. Pharm. (2008) 356: 282-290.
24. Salem II and Duzgunes N. Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages. Int. J. Pharm. (2003) 250: 403-414.
25. Inoue Y, Yoshimura S, Tozuka Y, Moribe K, Kumamoto T, Ishikawa T and Yamamoto K. Application of ascorbic acid 2-glucoside as a solubilizing agent for clarithromycin: solubilization and nanoparticle formation. Int. J. Pharm. (2007) 331: 38-45.
26. Lu Y, Zhang Y, Yang Z and Tang X. Formulation of an intravenous emulsion loaded with a clarithromycin-phospholipid complex and its pharmacokinetics in rats. Int. J. Pharm. (2009) 366: 160-169.
27. Ain-Ai A and Gupta PK. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. Int. J. Pharm. (2008) 351: 282-288.
28. Ali HSM, York P and Blagden N. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int. J. Pharm. (2009) 375: 107-113.
29. Wu L, Zhang J and Watanabe W. Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev. (2011) 63: 456-469.
30. Cao L-y, Zhang C-b and Huang J-f. Synthesis of hydroxyapatite nanoparticles in ultrasonic precipitation. Ceramics Int. (2005) 31: 1041-1044.
31. Xia X, Shen LL, Guo ZP, Liu HK and Walter G. Nanocrystalline alpha-Ni(OH)2 prepared by ultrasonic precipitation. J. Nanosci Nanotechnol. (2002) 2: 45-46.
32. Van Eerdenbrugh B, Vermant J, Martens JA, Froyen L, Van Humbeeck J, Augustijns P and Van den Mooter G. A screening study of surface stabilization during the production of drug nanocrystals. J. Pharm. Sci. (2009) 98: 2091-2103.
33. Monnier H, Wilhelm AM and Delmas H. Influence of ultrasound on mixing on the molecular scale for water and viscous liquids. Ultr. Sonochem. (1999) 6: 67-74.
34. Noyes AA and Whitney WR. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. (1897) 19: 930-934.
35. Singhal D and Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. Rev. (2004) 56: 335-347.